Media coverage
10
Media coverage
Title Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA® (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease Media name/outlet BioSpace Country/Territory United States Date 23/10/23 URL ct.moreover.com/?a=52133901586&p=1gw&v=1&x=3OMeOUUHMn3kqEdXcNwsWA Persons Jean-Frédéric Colombel Title Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA® (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease Media name/outlet PipelineReview Country/Territory Spain Date 23/10/23 URL ct.moreover.com/?a=52134297309&p=1gw&v=1&x=LLwOHaT2f0X5GIdNwgUTDg Persons Jean-Frédéric Colombel Title Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA® (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease Media name/outlet WTNZ Country/Territory United States Date 23/10/23 URL ct.moreover.com/?a=52132511491&p=1gw&v=1&x=mG1_Y9Ahy5FjnNXiHczMxg Persons Jean-Frédéric Colombel Title Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA® (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease Media name/outlet SouthEast - News Channel Nebraska Country/Territory United States Date 23/10/23 URL ct.moreover.com/?a=52132584797&p=1gw&v=1&x=ni6K21BUXOSW2tm_i3nXsQ Persons Jean-Frédéric Colombel Title Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA® (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease Media name/outlet 96.7 3WZ-FM Country/Territory United States Date 23/10/23 URL ct.moreover.com/?a=52133853362&p=1gw&v=1&x=ndHMVt86ozgQbfuBEBjizg Persons Jean-Frédéric Colombel Title Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA® (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease Media name/outlet Business Wire Country/Territory United States Date 22/10/23 URL ct.moreover.com/?a=52131888873&p=1gw&v=1&x=3Xk-w5zahm7-_rY9bht9Zw Persons Jean-Frédéric Colombel Title Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA® (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease Media name/outlet Street Insider Country/Territory United States Date 22/10/23 URL ct.moreover.com/?a=52131876385&p=1gw&v=1&x=SS6dgGRb-v-RdbN0bQGmAQ Persons Jean-Frédéric Colombel Title Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA® (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease Media name/outlet AFP Country/Territory France Date 22/10/23 URL ct.moreover.com/?a=52131935671&p=1gw&v=1&x=A_lQVbkPgElnDUncUbzbyA Persons Jean-Frédéric Colombel Title Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA® (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease Media name/outlet Yahoo! Finance Country/Territory United States Date 22/10/23 URL ct.moreover.com/?a=52134705451&p=1gw&v=1&x=Po5xyatIvjY6Bd-ILWiv3w Persons Jean-Frédéric Colombel Title Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA® (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease Media name/outlet ADVFN US Country/Territory United States Date 22/10/23 URL ct.moreover.com/?a=52131879753&p=1gw&v=1&x=UZlqNPLBUj2SZsaCqLO-JQ Persons Jean-Frédéric Colombel